High levels of follicular fluid testosterone could impair oocyte developmental competency via affecting aryl hydrocarbon receptor pathway in PCOS patients

Table 1 The clinical and hormonal characteristics of PCOS patients

Groups	Non-HFT-PCOS	HFT-PCOS	P value
Age (years)	30.14 ± 2.28	29.43 ± 2.73	NS: 0.84
BMI (kg/m2)	26.57 ± 0.64	25.29 ± 0.61	NS: 0.93
FSH (mIU/ml)	6.28 ± 0.56	6.42 ± 0.28	NS: 0.78
LH (mIU/ml)	7.93 ± 0.55	7.14 ± 0. 46	NS: 0.39
AMH	4.04 ± 0.28	4.71 ± 0.43	NS: 0.15
PRL	15.01 ± 1.12	14.94 ± 1.09	NS: 0.78
Days of ovarian stimulation	10.12 ± 1.67	10.54 ± 1.13	NS: 0.64
Total gonadotropin dose (IU)	2054 ± 345	1970 ± 278	NS: 0.48
Modified F-G Score	7.45 ± 1.17	8.01 ± 1.09	NS: 0.22
FFT (ng/ml)	3.41 ± 0.38	5.14 ± 0.42	0.01*
AFC	18.86 ± 1.22	17.42 ± 1.39	NS:0.46
GV oocytes (No)	2.86 ± 0.41	4.85 ± 0.67	0.025*
MI oocytes	1.53 ± 0.26	1.64 ± 0.44	NS:0.99
MII oocytes	11.86 ± 0.86	9.71 ± 0.97	0.044*
Fertilization rate (%)	76.14 ± 3.81	64.57 ± 3.57	0.039*
Cleavage rate (%)	72.43 ± 3.22	62.15 ± 3.61	0.032*
Grade A embryo (No)	7 .00 ± 049	5.43 ± 0.52	0.049*
Grade C embryo (No)	4.71 ± 0.42	5.00 ± 0.62	NS: 0.71

The data were presented as mean ± SEM
HFT high follicular fluid testosterone, PCOS polycystic ovary syndrome, BMI body mass index, FSH follicle-stimulating hormone, LH luteinizing hormone, PRL prolactin, AMH anti-Mullerian hormone, F-G Score Ferriman and Gallwey score, FFT follicular fluid testosterone, AFC antral follicular count, GV germinal vesicle, MI metaphase I, MII metaphase II
^*Significance values

ISSN: 2661-8850